

# Endometrial Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/EAE7F13C98BEN.html>

Date: May 2020

Pages: 1456

Price: US\$ 2,000.00 (Single User License)

ID: EAE7F13C98BEN

## Abstracts

Endometrial Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Pipeline Review, H1 2020, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved

in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 74, 66, 3, 12, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 1 and 2 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Endometrial Cancer - Therapeutics Assessment

Endometrial Cancer - Companies Involved in Therapeutics Development

Endometrial Cancer - Drug Profiles

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Endometrial Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Endometrial Cancer - Pipeline by Aadi Bioscience Inc, H1 2020

Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020

Endometrial Cancer - Pipeline by Abpro Corp, H1 2020

Endometrial Cancer - Dormant Projects, H1 2020

Endometrial Cancer - Discontinued Products, H1 2020

Endometrial Cancer - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Endometrial Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Aadi Bioscience Inc  
Ability Pharmaceuticals SL  
Abpro Corp  
Acepodia Biotech Inc  
Acrotech Biopharma LLC  
Adlai Nortye Biopharma Co Ltd  
Advenchen Laboratories LLC  
Agenus Inc  
Almac Discovery Ltd  
Amgen Inc  
Apexian Pharmaceuticals Inc  
Apexigen Inc  
Apollomics Inc  
Arcus Biosciences Inc  
Arrien Pharmaceuticals LLC  
Ascenta Therapeutics Inc  
AstraZeneca Plc  
Bantam Pharmaceutical LLC  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd

Beijing Neoantigen Biotechnology Co Ltd  
Bicycle Therapeutics Plc  
Bio-Path Holdings Inc  
BioMed Valley Discoveries Inc  
BioNTech SE  
Black Diamond Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Bristol-Myers Squibb Co  
Byondis BV  
Carrick Therapeutics Ltd  
Celon Pharma SA  
Celsion Corp  
Checkpoint Therapeutics Inc  
Clovis Oncology Inc  
Compugen Ltd  
Context Therapeutics LLC  
Corvus Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
Cue Biopharma Inc  
Cyclacel Pharmaceuticals Inc  
Daiichi Sankyo Co Ltd  
Deciphera Pharmaceuticals Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Elicio Therapeutics  
ENB Therapeutics LLC  
Epizyme Inc  
Esperance Pharmaceuticals Inc  
Esperas Pharma Inc  
EstryX Pharma Ltd  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Fujifilm Holdings Corp  
GamaMabs Pharma SA  
Genmab AS  
GlaxoSmithKline Plc  
Gradalis Inc  
Hanmi Pharmaceuticals Co Ltd  
Harbin Gloria Pharmaceuticals Co Ltd



Hebei Senlang Biotechnology Inc Ltd  
Horizon Therapeutics Plc  
Hutchison MediPharma Ltd  
Immunocore Ltd  
ImmunoGen Inc  
Immunomedics Inc  
Incyte Corp  
Innate Pharma SA  
Innovent Biologics Inc  
Jiangsu Hengrui Medicine Co Ltd  
Karyopharm Therapeutics Inc  
Komipharm International Co Ltd  
Laekna Therapeutics Shanghai Co Ltd  
Leap Therapeutics Inc  
Merck & Co Inc  
Merck KGaA  
Mereo Biopharma Group Plc  
Mersana Therapeutics Inc  
Merus NV  
Millennium Pharmaceuticals Inc  
Moderna Inc  
Molecular Partners AG  
Molecular Templates Inc  
NeoTX Therapeutics Ltd  
NextCure Inc  
Northlake International LLC  
Novartis AG  
NovaTarg Therapeutics Inc  
Oncoceutics Inc  
Oncologie Inc  
Oncology Venture U.S. Inc  
OncoResponse Inc  
Ono Pharmaceutical Co Ltd  
Orano Med LLC  
Pfizer Inc  
Pharma Mar SA  
Pieris Pharmaceuticals Inc  
PRISM Pharma Co Ltd  
PTC Therapeutics Inc

Puma Biotechnology Inc  
Samumed LLC  
Sanofi  
SELLAS Life Sciences Group Inc  
Shanghai Junshi Bioscience Co Ltd  
Splash Pharmaceuticals Inc  
Spring Bank Pharmaceuticals Inc  
SpringWorks Therapeutics Inc  
Sutro Biopharma Inc  
Syndax Pharmaceuticals Inc  
Taiho Pharmaceutical Co Ltd  
Unum Therapeutics Inc  
Vyriad Inc  
Xencor Inc  
Zymeworks Inc

## I would like to order

Product name: Endometrial Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/EAE7F13C98BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EAE7F13C98BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970